E0

ALS Biomarkers Are Entering the Approval Fight

Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.

Prevention Is Now Alzheimer’s Hardest Trial

Microglia Are Not a Shortcut to Alzheimer’s Certainty

Down Syndrome Cannot Stay Outside Alzheimer’s Trials

Cataplexy Is Waiting on an FDA Clock

AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?

A Blood Test Will Not Fix Colorectal Screening by Itself

Tau Is Back. Certainty Is Not.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
